Ind-Swift Laboratories Share Price

Ind-Swift Laboratories Investment Rating

• Master Rating:

• Ind-Swift Labs. (Nse) has an operating revenue of Rs. 1,069.10 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 1% needs improvement, ROE of -0% is poor and needs improvement. The company has a high debt to equity of 141%, which can be a reason to worry. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 17 which is a POOR score indicating inconsistency in earnings, a RS Rating of 21 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 97 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.